Caris Life Sciences, an Irving, TX-based AI TechBio company and precision medicine provider, raised $168M in Growth funding.
The round was led by Braidwell LP, with participation from new investors Perceptive Advisors, Woodline and Ghisallo, along with additional new investor including Millennium Management and First Light Asset Management.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO and Founder David D. Halbert, Caris Life Sciences is an AI TechBio company and precision medicine provider that is actively developing and delivering solutions to improve healthcare and human conditions. Through comprehensive molecular profiling (whole exome and whole transcriptome sequencing) and the application of advanced AI and machine learning algorithms, it has created a multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver new precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
With this funding, Caris has raised $1.86 billion in capital since 2018.
The company has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland.
FinSMEs
07/04/2025